Israel Englander’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $151M | Sell |
599,100
-203,400
| -25% | -$43.8M | 0.05% | 339 |
|
|
2026
Q1 | $175M | Buy |
802,500
+62,300
| +8% | +$13.8M | 0.07% | 244 |
|
|
2025
Q4 | $169M | Sell |
740,200
-19,800
| -3% | -$4.51M | 0.07% | 244 |
|
|
2025
Q3 | $176M | Buy |
760,000
+305,300
| +67% | +$62.2M | 0.08% | 222 |
|
|
2025
Q2 | $84.4M | Sell |
454,700
-663,200
| -59% | -$123M | 0.04% | 497 |
|
|
2025
Q1 | $234M | Buy |
1,117,900
+612,300
| +121% | +$119M | 0.12% | 118 |
|
|
2024
Q4 | $89.8M | Sell |
505,600
-27,300
| -5% | -$5.02M | 0.04% | 440 |
|
|
2024
Q3 | $105M | Sell |
532,900
-482,200
| -48% | -$90M | 0.05% | 389 |
|
|
2024
Q2 | $174M | Buy |
1,015,100
+67,100
| +7% | +$11.1M | 0.08% | 232 |
|
|
2024
Q1 | $173M | Sell |
948,000
-252,000
| -21% | -$43.4M | 0.07% | 247 |
|
|
2023
Q4 | $186M | Sell |
1,200,000
-124,900
| -9% | -$18.2M | 0.08% | 192 |
|
|
2023
Q3 | $197M | Buy |
1,324,900
+545,500
| +70% | +$80.1M | 0.1% | 145 |
|
|
2023
Q2 | $105M | Sell |
779,400
-410,100
| -34% | -$60.1M | 0.05% | 348 |
|
|
2023
Q1 | $190M | Sell |
1,189,500
-363,100
| -23% | -$55.5M | 0.11% | 127 |
|
|
2022
Q4 | $251M | Buy |
1,552,600
+600,400
| +63% | +$92.1M | 0.14% | 100 |
|
|
2022
Q3 | $128M | Sell |
952,200
-121,600
| -11% | -$17.4M | 0.08% | 221 |
|
|
2022
Q2 | $164M | Sell |
1,073,800
-1,023,900
| -49% | -$156M | 0.1% | 127 |
|
|
2022
Q1 | $340M | Sell |
2,097,700
-914,900
| -30% | -$133M | 0.18% | 53 |
|
|
2021
Q4 | $408M | Buy |
3,012,600
+1,534,800
| +104% | +$181M | 0.21% | 57 |
|
|
2021
Q3 | $159M | Sell |
1,477,800
-260,000
| -15% | -$29.7M | 0.1% | 161 |
|
|
2021
Q2 | $196M | Buy |
1,737,800
+45,700
| +3% | +$5.15M | 0.12% | 105 |
|
|
2021
Q1 | $183M | Buy |
1,692,100
+790,500
| +88% | +$84.6M | 0.13% | 98 |
|
|
2020
Q4 | $96.6M | Buy |
901,600
+550,400
| +157% | +$52.9M | 0.07% | 222 |
|
|
2020
Q3 | $30.8K | Sell |
351,200
-4,000
| -1% | -$377K | 0.04% | 547 |
|
|
2020
Q2 | $34.9M | Sell |
355,200
-673,900
| -65% | -$59.3M | 0.05% | 454 |
|
|
2020
Q1 | $78.4M | Buy |
1,029,100
+363,000
| +54% | +$30.9M | 0.18% | 92 |
|
|
2019
Q4 | $59M | Buy |
666,100
+498,300
| +297% | +$41.4M | 0.07% | 300 |
|
|
2019
Q3 | $12.7M | Buy |
+167,800
| New | +$11.5M | 0.02% | 1108 |
|
|
2014
Q4 | – | Sell |
-5,000
| Closed | -$178K | – | 3865 |
|
|
2014
Q3 | $178K | Sell |
5,000
-600
| -11% | -$33.3K | ﹤0.01% | 3463 |
|
|
2014
Q2 | $316K | Buy |
+5,600
| New | +$294K | ﹤0.01% | 2842 |
|
Other funds holding ABBV
Israel Englander's ABBV Position: Q2 2026 in Review
Israel Englander increased its AbbVie (ABBV) stake by 124% in Q2 2026, buying an estimated $181M and bringing the position to 1,516,475 shares worth $382M. The position accounts for 0.14% of the portfolio, ranked #101.
Israel Englander first reported a position in ABBV in Q2 2013 and has held it in 50 quarters since. The position peaked at $467M in Q3 2025. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Israel Englander held 1,516,475 shares of AbbVie worth $382M as of Q2 2026.
- Israel Englander bought 840,718 AbbVie shares in Q2 2026, an estimated $181M.
- AbbVie made up 0.14% of Israel Englander's portfolio in Q2 2026, its #101 holding.
- Israel Englander first reported a position in AbbVie in Q2 2013 and has held it in 50 quarters since.
- Israel Englander's AbbVie position peaked at $467M in Q3 2025.
- 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.